Evidence map›Paper›PMID 38132789›Full record

ReviewJournal of fungi (Basel, Switzerland)2023

In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in

Iacopo Franconi, Antonella Lupetti

Open access · goldAbstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Urinary tract infection caused by rare yeastFrontiers in immunology · 2026
    Review
  7. Antifungal activity of guanidine compounds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  8. Article
  9. Article
  10. Rapid Identification of Clinically RelevantJournal of fungi (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Chitosan-silver nanocomposites: promising alternatives for combating azole-resistantFrontiers in cellular and infection microbiology · 2025
    Article
  13. Comparative Genomic Analysis of anPolish journal of microbiology · 2024
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Iacopo FranconiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0003-2525-6216
Antonella LupettiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-6975-8114
University of Pisa · IT

Funding

European Union-NextGenerationEU, PNRR «THE» (Tuscany health ecosystem), Spoke 7: Inno-vating translational medicine, Sub-project 5 Project Code: ECS00000017, CUP I53C22000780001)
6 · The paper itself

Abstract

Antimicrobial resistance is a matter of rising concern, especially in fungal diseases. Multiple reports all over the world are highlighting a worrisome increase in azole- and echinocandin-resistance among fungal pathogens, especially in

Indexed as

antifungal resistanceantifungal susceptibility testingantifungal toleranceCandida spp. fungicidal testsminimum fungicidal concentrationserum fungicidal concentrationtime-kill curve analysis

Identifiers

PMID38132789
PMCPMC10744879
OpenAlexW4389625049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.